# EvidenceOS PRIME V2.2 - Feature Enhancements Plan

## 🚀 STRATEGIC ENHANCEMENTS TO 21 FEATURES

This document outlines comprehensive enhancements to make each feature best-in-class.

---

## PHASE 1: CRITICAL HTA METHODS

### 1. MAIC/STC Engine ✅ → ⭐ ENHANCED

**Current State**: Production-ready MAIC with entropy balancing

**Enhancements**:
- ✅ Add STC (Simulated Treatment Comparison) full implementation
- ✅ Cross-validation for variable selection
- ✅ Sensitivity analysis with multiple scenarios
- ✅ Propensity score trimming options (fixed, adaptive)
- ✅ Multiple weighting methods (entropy, logistic, CBPS)
- ✅ Bootstrapped confidence intervals for all estimates
- ⭐ Calibration diagnostics
- ⭐ Synthetic control methods integration

**Value Add**: Regulatory-grade flexibility for different HTA agencies

---

### 2. Target Trial Emulation ✅ → ⭐ ENHANCED

**Current State**: IPW, g-formula, clone-censor-weight

**Enhancements**:
- ✅ Add Marginal Structural Models (MSM)
- ✅ G-estimation for structural nested models
- ✅ Time-varying confounder handling
- ⭐ Instrumental variable approaches
- ⭐ Doubly robust estimation (DR)
- ⭐ Sequential trial emulation
- ⭐ Immortal time bias detection

**Value Add**: Complete causal inference toolkit

---

### 3. Multi-State Models ✅ → ⭐ ENHANCED

**Current State**: Markov cohort models with ODE solver

**Enhancements**:
- ✅ Add Competing Risks framework
- ✅ Semi-Markov models (time-dependent transitions)
- ✅ Non-homogeneous Markov (time-varying rates)
- ⭐ Multi-state survival analysis (Aalen-Johansen estimator)
- ⭐ Microsimulation option
- ⭐ Tunnel states for temporary states
- ⭐ Integration with survival extrapolation

**Value Add**: Handle complex disease progressions

---

### 4. HTA Dossier Generator ✅ → ⭐ ENHANCED

**Current State**: ICER, CEAC, EVPI, budget impact

**Enhancements**:
- ✅ Add 10+ country packs (Australia, Japan, Netherlands, Spain, Italy, Sweden, Norway, Brazil, China, India)
- ✅ Automated GRADE assessment integration
- ✅ Automated executive summary generation
- ⭐ NICE submission template
- ⭐ EMA/FDA evidence synthesis template
- ⭐ Automated quality assessment (AMSTAR-2, ROBIS)
- ⭐ Living HTA dossier with version tracking

**Value Add**: One-click regulatory submissions

---

## PHASE 2: AI & AUTOMATION

### 5. ML Citation Screening ✅ → ⭐ ENHANCED

**Current State**: TF-IDF + LogReg (82% precision, 93% recall)

**Enhancements**:
- ✅ Add BERT/BioBERT/PubMedBERT option (real transformers)
- ✅ Model calibration with Platt scaling
- ✅ Ensemble methods (TF-IDF + BERT)
- ✅ Cross-validation with stratified splits
- ⭐ Transfer learning from pre-screened datasets
- ⭐ Uncertainty quantification (MC Dropout)
- ⭐ Explainability (LIME, SHAP)
- ⭐ Integration with Covidence, DistillerSR APIs

**Value Add**: 95%+ recall with explainability

---

### 6. Data Extraction ✅ → ⭐ ENHANCED

**Current State**: Regex pattern matching (40-60% accuracy)

**Enhancements**:
- ✅ Add spaCy NER for real entity extraction
- ✅ Table extraction from PDFs (tabula-py, camelot)
- ✅ OCR integration (tesseract) for scanned PDFs
- ⭐ Fine-tuned BioBERT for biomedical entities
- ⭐ Relation extraction (intervention-outcome pairs)
- ⭐ Multi-modal extraction (text + figures)
- ⭐ Active learning for improving extraction

**Value Add**: 80%+ extraction accuracy with tables/OCR

---

### 7. Living Systematic Reviews ✅ → ⭐ ENHANCED

**Current State**: Version tracking, delta reports

**Enhancements**:
- ✅ Add automated PubMed/Embase search scheduling
- ✅ Email alerts for new studies
- ✅ Automated deduplication across versions
- ⭐ Integration with citation screening
- ⭐ Automated re-analysis triggers
- ⭐ Living GRADE assessment
- ⭐ Publication-ready living MA reports

**Value Add**: Fully automated living MA pipeline

---

### 8. PRISMA 2020 Compliance ✅ → ⭐ ENHANCED

**Current State**: 27-item checklist, flow diagrams

**Enhancements**:
- ✅ Add automated flow diagram generation from data
- ✅ PRISMA-P protocol template
- ✅ PRISMA-S search reporting checklist
- ⭐ PRISMA-DTA for diagnostic test accuracy
- ⭐ PRISMA-IPD checklist
- ⭐ Automated reporting quality assessment
- ⭐ Export to all journal formats

**Value Add**: Complete PRISMA ecosystem

---

## PHASE 3: ADVANCED STATISTICS

### 9. Propensity Score Analysis ✅ → ⭐ ENHANCED

**Current State**: PSM, IPW, stratification

**Enhancements**:
- ✅ Add Optimal Matching (minimize total distance)
- ✅ Genetic Matching (multivariate balance)
- ✅ CBPS (Covariate Balancing Propensity Score) full implementation
- ✅ Entropy balancing
- ⭐ Prognostic score matching
- ⭐ PS with machine learning (random forest, GBM)
- ⭐ Overlap weights
- ⭐ Love plots and balance diagnostics suite

**Value Add**: Best-in-class PS methods

---

### 10. IPD Meta-Analysis ✅ → ⭐ ENHANCED

**Current State**: MixedLM with random intercepts

**Enhancements**:
- ✅ Add Random Slopes (treatment-by-covariate interactions)
- ✅ Three-level models (patients within studies within countries)
- ✅ Bayesian IPD MA (PyMC/JAGS)
- ⭐ IPD Network Meta-Analysis
- ⭐ Time-to-event IPD MA (frailty models)
- ⭐ Penalized splines for non-linear effects
- ⭐ Missing data handling (multiple imputation)

**Value Add**: Handle complex IPD structures

---

### 11. Threshold Analysis ✅ → ⭐ ENHANCED

**Current State**: WTP threshold, CEAC, EVPI

**Enhancements**:
- ✅ Add EVPPI (Expected Value of Partial Perfect Information)
- ✅ VOI (Value of Information) curves
- ✅ EVSI (Expected Value of Sample Information)
- ⭐ Bayesian EVPPI with GAM regression
- ⭐ Multi-parameter EVPPI
- ⭐ Optimal sample size calculations
- ⭐ Research prioritization framework

**Value Add**: Complete VOI analysis for research planning

---

### 12. Survival Model Validation ⚠️ → ⭐ NEW IMPLEMENTATION

**Current State**: Uses multi-state framework

**Enhancements**:
- ✅ Calibration plots (predicted vs observed)
- ✅ Time-dependent AUC/C-statistic
- ✅ Brier score for survival
- ⭐ Harrell's C-index
- ⭐ Royston-Parmar flexible parametric models
- ⭐ Model selection criteria (AIC, BIC, C-index)
- ⭐ External validation framework

**Value Add**: Regulatory-grade survival validation

---

### 13. Component NMA ✅ → ⭐ ENHANCED

**Current State**: WLS with interactions

**Enhancements**:
- ✅ Bayesian hierarchical component NMA
- ✅ Prior sensitivity analysis
- ✅ Component selection via LASSO/Elastic Net
- ⭐ Three-level hierarchy (components, treatments, studies)
- ⭐ Network component comparison
- ⭐ Component importance via SUCRA
- ⭐ Optimal treatment combination search

**Value Add**: Identify best component combinations

---

## PHASE 4: USABILITY

### 14. Reference Manager Integration ⚠️ → ✅ NEW IMPLEMENTATION

**Current State**: Not implemented

**Enhancements**:
- ✅ Zotero API integration (read/write)
- ✅ Mendeley API integration
- ✅ EndNote XML import/export
- ✅ BibTeX import/export
- ⭐ RIS format support
- ⭐ Automated citation updates
- ⭐ Duplicate detection across managers
- ⭐ Full-text PDF linking

**Value Add**: Seamless reference workflow

---

### 15. Interactive Visualizations ✅ → ⭐ ENHANCED

**Current State**: Plotly, ggplot2 plots

**Enhancements**:
- ✅ Add interactive forest plots with drill-down
- ✅ Network graphs with node sizing
- ✅ CE plane with zoom/pan
- ⭐ Tornado diagrams (interactive)
- ⭐ Waterfall plots for EVPPI
- ⭐ Sankey diagrams for multi-state models
- ⭐ Animated transitions for living MA
- ⭐ Export to interactive HTML

**Value Add**: Publication-ready interactive visuals

---

### 16. CE Planes & CEAC ✅ → ⭐ ENHANCED

**Current State**: Static CE planes, CEAC

**Enhancements**:
- ✅ Add probabilistic CE planes (2D density)
- ✅ CEAF (Cost-Effectiveness Acceptability Frontier)
- ✅ Multi-way CE comparison
- ⭐ CE efficiency frontier
- ⭐ Net health benefit plots
- ⭐ Animated CE planes for sensitivity
- ⭐ Country-specific WTP overlays

**Value Add**: Complete CE visualization suite

---

### 17. Collaboration Tools ✅ → ⭐ ENHANCED

**Current State**: Client portal (read-only)

**Enhancements**:
- ✅ Add real-time collaboration (websockets)
- ✅ Comment/annotation system
- ✅ Version history with diff
- ⭐ Role-based access control (RBAC)
- ⭐ Audit trail for all changes
- ⭐ Git-like branching for analyses
- ⭐ Team workspaces
- ⭐ Export permissions management

**Value Add**: Enterprise collaboration platform

---

## PHASE 5: ADVANCED METHODS

### 18. REML Estimation ✅ → ⭐ ENHANCED

**Current State**: Multiple estimators in metafor

**Enhancements**:
- ✅ Add Bayesian REML via Stan
- ✅ Profile likelihood CI for τ²
- ✅ Hartung-Knapp adjustment
- ⭐ Paule-Mandel estimator
- ⭐ Empirical Bayes estimator
- ⭐ Estimator comparison diagnostics
- ⭐ Automated estimator selection

**Value Add**: Robust heterogeneity estimation

---

### 19. Dose-Response MA ✅ → ⭐ ENHANCED

**Current State**: RCS, natural splines

**Enhancements**:
- ✅ Add full RCS implementation (rms package equivalent)
- ✅ Fractional polynomials
- ✅ Non-linear dose-response with dosresmeta
- ⭐ Bayesian dose-response (JAGS)
- ⭐ Multi-variable dose-response
- ⭐ Time-varying dose effects
- ⭐ Threshold detection

**Value Add**: Publication-ready dose-response curves

---

### 20. Federated Analysis ⚠️ → ✅ NEW IMPLEMENTATION

**Current State**: Not implemented

**Enhancements**:
- ✅ Privacy-preserving distributed MA
- ✅ Secure aggregation protocols
- ✅ Differential privacy mechanisms
- ⭐ Homomorphic encryption option
- ⭐ Multi-site IPD MA without data sharing
- ⭐ Federated learning for AI models
- ⭐ Audit trails for compliance

**Value Add**: GDPR/HIPAA-compliant multi-site analysis

---

### 21. Budget Impact Analysis ✅ → ⭐ ENHANCED

**Current State**: 5-year projections, linear uptake

**Enhancements**:
- ✅ Add non-linear uptake curves (S-curve, Gompertz)
- ✅ Scenario comparison (best/worst/likely)
- ✅ Budget constraint optimization
- ⭐ Disinvestment analysis
- ⭐ Return on investment (ROI) calculations
- ⭐ Multi-indication budget impact
- ⭐ Dynamic pricing sensitivity
- ⭐ Affordability thresholds

**Value Add**: Complete budget planning toolkit

---

## 📊 IMPLEMENTATION PRIORITY

### HIGH PRIORITY (Implement in V2.2)
1. ✅ Reference Manager Integration
2. ✅ EVPPI/VOI for Threshold Analysis
3. ✅ GRADE Assessment Module
4. ✅ Bayesian NMA
5. ✅ Federated Analysis Framework
6. ✅ Optimal Matching for PS
7. ✅ Random Slopes for IPD MA
8. ✅ BERT Option for Citation Screening
9. ✅ spaCy NER for Data Extraction
10. ✅ Survival Model Validation

### MEDIUM PRIORITY (V2.3)
- Competing risks for multi-state
- MSM for target trials
- Ensemble screening methods
- Automated search scheduling
- Three-level IPD models

### FUTURE (V3.0)
- Microsimulation
- Federated learning
- Explainable AI
- Automated GRADE
- Real-time collaboration

---

## 💰 BUSINESS IMPACT

**Revenue Multipliers**:
- Reference Manager Integration: +£50k (workflow efficiency)
- GRADE Assessment: +£100k (regulatory requirement)
- Bayesian NMA: +£150k (advanced methods premium)
- EVPPI/VOI: +£75k (research planning contracts)
- Federated Analysis: +£200k (multi-site studies)
- BERT Screening: +£50k (accuracy improvement)

**Total Additional Revenue Potential**: +£625k/year

**Time Savings**:
- Reference integration: 10 hours/project
- GRADE: 15 hours/project
- Automated validation: 5 hours/project

**Total Time Savings**: 30 hours/project = 37% faster delivery

---

## 🎯 SUCCESS METRICS

**Technical**:
- All features > 95% accuracy
- API response < 2 seconds
- 100% test coverage
- Zero security vulnerabilities

**Business**:
- 50+ regulatory submissions using platform
- 10+ pharmaceutical clients
- £2M+ annual revenue
- 5-star client satisfaction

---

## ⏱️ DEVELOPMENT TIMELINE

**Sprint 1 (Week 1-2)**: Reference Manager, GRADE, EVPPI
**Sprint 2 (Week 3-4)**: Bayesian NMA, Federated Analysis
**Sprint 3 (Week 5-6)**: BERT, spaCy, Survival Validation
**Sprint 4 (Week 7-8)**: Advanced PS, IPD MA random slopes
**Sprint 5 (Week 9-10)**: Testing, documentation, deployment

**Total**: 10 weeks to production-grade V2.2

---

*This roadmap ensures EvidenceOS PRIME remains the most advanced HTA platform globally.*
